Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S001 - Hot Topics in Medical Dermatology

Thursday, July 26; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Select optimal therapies for patients with a number of cutaneous disorders including psoriasis and atopic dermatitis.
  • Identify the cutaneous manifestations of various travelers dermatoses
  • Diagnose and treat life-threatening dermatoses such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and immunobullous diseases more effectively


Topics to be covered include new developments in the diagnosis and treatment of skin cancers; epidemiology and diagnosis of travelers dermatoses including viruses such as Zika, Chikungunya and dengue; new treatments for psoriasis and atopic dermatitis; clinical manifestations in treatments for new developments in topical therapy; and new developments in medical and pediatric dermatology


  • Golant, Alexandra Kerner, MD: Sanofi/Regeneron – SP(H); UCB – A(H);
  • Gordon, Kenneth B., MD: AbbVie – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – A(H), I(Grants/Research Funding); Demira – C(H); Dermavant Sciences – C(H); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H); Lilly ICOS LLC – A(H); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Othro Dermatologics – C(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Levitt, Jacob, MD: AbbVie – C(H); Amgen – A(H); Biofrontera AG – A(H); Castle Biosciences, Inc – A(H); Corrona, Inc. – I(Fees); Eli Lilly and Company – A(H); Janssen Pharmaceuticals, Inc – A(H); Medscape – C(H); Menlo Therapeutics – A(H); Novartis – C(H); Pfizer Inc. – A(H); Ranbaxy Laboratories Limited – A(H); Regeneron Pharmaceuticals, Inc. – A(H); Roche Laboratories – A(Fees); Springer Science & Business Media – O(OB); UCB – A(H); Valeant Pharmaceuticals North America LLC – A(H);
  • Paller, Amy S., MD: AbbVie – I(NC); Amgen – C(H), I(NC); Amicus Therapeutics – C(H); BridgeBio Pharma, LLC – A(H), C(H); Castle Creek Pharmaceuticals – C(H); Celgene Corporation – I(NC); Dermira – C(H); Eli Lilly and Company – C(H); Expanscience – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – C(H); Janssen Pharmaceuticals, Inc – I(NC); Leo Pharma Inc – I(Grants/Research Funding); Menlo Therapeutics – A(H), C(H); Novartis Pharmaceuticals Corp. – C(H); Pfizer Inc. – C(H); Regeneron – C(H); Sanofi/Regeneron – A(H); Stiefel a GSK company – C(H); Valeant Pharmaceuticals North America LLC – C(H);
  • Rigel, Darrell S., MD: Aclaris Therapeutics, Inc. – C(H); Beiersdorf, Inc. – A(H); Castle Biosciences – A(H), I(Grants/Research Funding); Derm Tech International – A(H), C(H); Ferndale Laboratories, Inc. – C(H); Foamix – SH(SO); LEO Pharma, US – A(H); Myriad Genetics Inc – A(H); Novartis – A(H); Ortho Dermatologics – A(H); Pierre Fabre Dermo-Cosmétique US – A(H); SciBASE – C(H);
  • Rosen, Theodore, MD: Foamix – A(H); Medimetriks Pharmaceuticals, Inc. – C(H); Menlo Therapeutics – A(H); Valeant Pharmaceuticals International – C(H);
  • Stein Gold, Linda F., MD: AbbVie – A(H); Actavis – SP(H); Allergan, Inc. – I(Grants/Research Funding); Aqua – A(H); Ferndale Laboratories, Inc. – C(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – A(H); Leo Pharma Inc. – I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – A(H); Medicis Pharmaceutical Corporation – A(H); Merz Pharmaceuticals, LLC – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Promius Pharmaceuticals – A(H); Roche Laboratories – Independent Contractor(Fees), O(H); Sol-Gel Technologies – C(Grants/Research Funding); Stiefel a GSK company – A(H); Taro Pharm – A(H), C(H); Topica – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding);
  • Tomecki, Kenneth J., MD: no financial relationships exist with commercial interests.
Thursday, July 26
9:00 AM
Dr. Lebwohl / Introduction
9:04 AM
Dr. Rigel / Hot Topics in Skin Cancer
9:23 AM
Dr. Rosen / The Hottest Topic: Sexually Transmitted Diseases
9:42 AM
Dr. Gordon / What's New in Psoriasis
10:01 AM
Dr. Paller / What's New in Pediatric Dermatology
10:20 AM
Dr. Stein Gold / What's New in Topical Therapy
10:39 AM
Dr. Golant / What's New in Atopic Dermatitis
10:58 AM
Dr. Tomecki / What You Have to Know About Traveler's Dermatoses
11:17 AM
Dr. Levitt / Dangerous Dermatoses: TEN, SJS, EM, BP, & PV Pearls
11:36 AM
Dr. Lebwohl / Hot Topics in Dermatology Practice
Event Details
  • Date
    Thursday, July 26
  • Time
    9:00 AM - 12:00 PM
  • Location
    Grand Ballroom EF
  • CME Credits
  • Type
  • Mark Lebwohl, MD, FAAD
  • Alexandra Kerner Golant, MD, FAAD
  • Amy S. Paller, MD, FAAD - Handout
  • Darrell S. Rigel, MD, FAAD
  • Jacob Levitt, MD, FAAD - Handout
  • Kenneth B. Gordon, MD, FAAD
  • Kenneth J. Tomecki, MD, FAAD
  • Linda F. Stein Gold, MD, FAAD
  • Theodore Rosen, MD, FAAD - Handout